MSI-H And dMMR: A Leading Driver Behind Rising Prevalence Of Cancer Is Fueling The Market Due To Increasing Demand For Personalized Immunotherapy Approaches Market Expansion in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the MSI-H And dMMR Industry Market Size Be by 2025?
In the past few years, there has been an astounding surge in the market size of MSI-H and dMMR. Its estimated progression is from $6.15 billion in 2024 to $7.57 billion in 2025, with a compound annual growth rate (CAGR) of 23.0%. The unprecedented growth during the historic period can be credited to the escalating number of colorectal and endometrial cancer cases, amplified genetic screening initiatives, escalating clinical acceptance of MSI tests, growing cognizance of inherited cancer syndromes, and a surge in the adoption of liquid biopsy.

What's the Long-Term Growth Forecast for the MSI-H And dMMR Market Size Through 2029?
The market for MSI-H and dMMR is projected to witness substantial expansion in the coming years, with a growth outlook of $17.26 billion in 2029, exhibiting a CAGR of 22.9%. Factors contributing to this growth trajectory during the forecast period include an escalating demand for custom cancer therapies, the broadening scope of next-generation sequencing, increasing expenditure on healare in the field of oncology, a surge in clinical trials encompassing immune checkpoint inhibitors, and proactive regulatory backing for companion diagnostics. Emerging trends during the forecasted timeline include the adoption of artificial intelligence in diagnostic workflows, collaborations between pharmaceutical and diagnostic entities, creation of multiplex biomarker panels, advancements in immunotherapy, and a transition towards pan-cancer biomarker testing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

What Are the Key Growth Drivers Fueling the MSI-H And dMMR Market Expansion?
The escalating occurrence of cancer is anticipated to foster growth in the MSI-H and dMMR market. Cancer, a collective term for a multitude of diseases, is characterized by unrestrained cell growth and expansion of abnormal cells in the body. The heightened cancer rates can be attributed mainly to aging populations, as the likelihood of cancer development substantially escalates with age owing to accumulated genetic mutations and extended risk exposure over time. MSI-H and dMMR are utilized in cancer to pinpoint tumors with high mutation frequencies resulting from impaired DNA repair mechanisms. These biomarkers are crucial in directing immunotherapy decisions because such tumors are more likely to respond favorably to immune checkpoint inhibitors. They also offer valuable prognosis information and insights into potential genetic syndromes. For example, in January 2024, the American Cancer Society, a non-profit organization based in the US, postulated that in 2023 there would be approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States. These figures are expected to rise in 2024, with an estimated 2,001,140 new cases of cancer and about 611,720 deaths, underscoring the persistent escalation in cancer incidence and mortality. Consequently, the growing prevalence of cancer is fueling the expansion of the MSI-H and dMMR market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

What Are the Key Trends Driving MSI-H And dMMR Market Growth?
Leading corporations in the MSI-H and dMMR market are concentrating on the creation of innovative therapies like combination therapy to improve overall treatment performance and upgrade patient results. Combination therapy for MSI-H and dMMR cancers utilises multiple treatments, frequently involving immunotherapy drugs such as checkpoint inhibitors or coupling immunotherapy with other treatments including chemotherapy, targeted therapy, or radiation. This method is designed to enhance the response to treatment, bypass resistance, and boost survival rates in patients with highly microsatellite unstable tumors or deficient mismatch repair. For example, in April 2025, Bristol-Myers Squibb Company, a pharmaceutical firm based in the US, was granted approval by the United States Food and Drug Administration (FDA) for the combined use of nivolumab (Opdivo) and ipilimumab (Yervoy) as an initial treatment for metastatic colorectal cancer (mCRC) exhibiting microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) characteristics, propelling treatment options for this tough subtype of cancer. This approval signifies a pivotal breakthrough in MSI-H and dMMR cancer treatment as it offers a new potent treatment choice targeting numerous pathways to enhance patient longevity and response rates, addressing the unfulfilled medical requirements of this group of patients.

How Is the MSI-H And dMMR Market Segmented?
The msi-h and dmmr market covered in this report is segmented -

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy
2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications
3) By Stage: Early Stages, Advanced Stages
4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:
1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Which Companies Are Leading the Charge in MSI-H And dMMR Market Innovation?
Major companies operating in the MSI-H and dMMR market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Which Regions Are Leading the Global MSI-H And dMMR Market in Revenue?
North America was the largest region in the MSI-H and dMMR market in 2024. The regions covered in the MSI-H and dMMR market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24324

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.